Answers are grounded in this paper and cite their sources.
We appreciate the author's clever suggestion, and Journal of Urologic Oncology would like to briefly summarize the level of clinical research related to this topic.Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for type 2 diabetes mellitus (T2DM), are garnering attention for their potential anticancer effects in prostate cancer (PCa).As reported in the letter, a recent meta-analysis reported a 28% reduction in PCa risk among T2DM patients using GLP-1RAs, compared to placebo or other antidiabetic agents [1].Preclinical data support tumor-suppressive actions through mechanisms such as reduced proliferation, apoptosis induction, and cell cycle arrest, with synergistic enhancement noted in combination with agents like docetaxel and metformin [2][3][4].These effects appear mediated by pathways including cAMP, ERK/MAPK, AKT/PI3K, AMPK, and mTOR [2,3].Despite encouraging preclinical outcomes, clinical studies directly evaluating GLP-1RAs for PCa remain scarce, and definitive therapeutic benefit has not been established [2,4,5] (Table 1).Preliminary evidence suggests additive benefit when combined with chemotherapy [2,3].Importantly, no data currently indicate increased PCa risk, alleviating some oncologic safety concerns [2,4].GLP-1RAs exhibit promising antitumor activity in experimental models of PCa.However, clinical application as a therapeutic option awaits further high-quality trials to confirm efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Young Hwii Ko (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: